Total Payments
$7,338
2024 Payments
$7,068
Companies
12
Transactions
31
Medicare Patients
2,287
Medicare Billing
$241,765
Payment Breakdown by Category
Consulting$5,600 (76.3%)
Food & Beverage$876.10 (11.9%)
Travel$861.45 (11.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,600 | 1 | 76.3% |
| Food and Beverage | $876.10 | 27 | 11.9% |
| Travel and Lodging | $861.45 | 3 | 11.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $6,586 | 7 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $191.92 | 7 | $0 (2024) |
| INTERCEPT PHARMACEUTICALS, INC. | $119.91 | 1 | $0 (2022) |
| ABBVIE INC. | $115.99 | 5 | $0 (2024) |
| Ambu Inc. | $97.98 | 1 | $0 (2024) |
| Ardelyx, Inc. | $48.77 | 2 | $0 (2024) |
| Ferring Pharmaceuticals Inc. | $42.30 | 2 | $0 (2024) |
| Medtronic, Inc. | $40.41 | 2 | $0 (2023) |
| Horizon Therapeutics plc | $29.10 | 1 | $0 (2023) |
| Axonics, Inc. | $23.17 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,068 | 23 | Amgen Inc. ($6,586) |
| 2023 | $132.86 | 6 | Medtronic, Inc. ($40.41) |
| 2022 | $136.23 | 2 | INTERCEPT PHARMACEUTICALS, INC. ($119.91) |
All Payment Transactions
31 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $22.05 | General |
| Category: LIVER DISEASE | ||||||
| 10/24/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $20.58 | General |
| Category: IMMUNOLOGY | ||||||
| 09/25/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Gastroenterology | ||||||
| 07/25/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: IMMUNOLOGY | ||||||
| 07/24/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.18 | General |
| Category: Gastroenterology | ||||||
| 05/30/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $64.75 | General |
| Category: Gastroenterology | ||||||
| 05/23/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.50 | General |
| 05/09/2024 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $27.84 | General |
| Category: IMMUNOLOGY | ||||||
| 05/08/2024 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.59 | General |
| Category: Gastroenterology | ||||||
| 04/19/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $31.41 | General |
| Category: IMMUNOLOGY | ||||||
| 04/04/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: GASTROENTEROLOGY | ||||||
| 03/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $5,600.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $57.68 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/23/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/22/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $607.69 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/22/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $196.08 | General |
| Category: Inflammation/Rare Disease | ||||||
| 03/13/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: IMMUNOLOGY | ||||||
| 02/07/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.03 | General |
| Category: Gastroenterology | ||||||
| 01/11/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: GASTROENTEROLOGY | ||||||
| 01/10/2024 | Ambu Inc. | — | Food and Beverage | Cash or cash equivalent | $97.98 | General |
| 12/20/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: Gastroenterology | ||||||
| 12/01/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $18.21 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 482 | 556 | $353,354 | $52,480 |
| 2022 | 16 | 571 | 583 | $524,363 | $56,126 |
| 2021 | 18 | 663 | 1,578 | $597,712 | $74,676 |
| 2020 | 16 | 571 | 593 | $569,105 | $58,483 |
Total Patients
2,287
Total Services
3,310
Medicare Billing
$241,765
Procedure Codes
64
All Medicare Procedures & Services
64 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 77 | 80 | $36,182 | $10,374 | 28.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 61 | 114 | $25,878 | $10,266 | 39.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 46 | 46 | $80,854 | $9,122 | 11.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 69 | 74 | $97,568 | $5,447 | 5.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 45 | $11,411 | $3,130 | 27.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 48 | $7,764 | $2,874 | 37.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $9,180 | $2,165 | 23.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 13 | 13 | $18,861 | $2,151 | 11.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 12 | 12 | $6,030 | $1,487 | 24.7% |
| 91010 | Study of esophagus to assess movement | Facility | 2023 | 36 | 36 | $10,620 | $1,361 | 12.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 13 | $4,572 | $1,212 | 26.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 14 | 14 | $14,806 | $1,184 | 8.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 16 | 16 | $25,756 | $1,041 | 4.0% |
| 91037 | Monitoring and recording of esophageal function through nasal tube with electrode | Facility | 2023 | 22 | 22 | $3,872 | $666.17 | 17.2% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 69 | 69 | $120,405 | $13,212 | 11.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 144 | 149 | $204,875 | $12,020 | 5.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 69 | 74 | $18,870 | $6,117 | 32.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 33 | 33 | $12,870 | $3,606 | 28.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 20 | 20 | $29,480 | $3,384 | 11.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 25 | 25 | $8,746 | $2,954 | 33.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 19 | 19 | $9,234 | $2,887 | 31.3% |
| 91010 | Study of esophagus to assess movement | Facility | 2022 | 48 | 48 | $14,160 | $2,326 | 16.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 13 | 13 | $6,370 | $2,041 | 32.0% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 22 | 22 | $35,442 | $1,537 | 4.3% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2022 | 11 | 13 | $32,968 | $1,259 | 3.8% |
About Dr. Rahul Shimpi, MD
Dr. Rahul Shimpi, MD is a Gastroenterology healthcare provider based in Clayton, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/21/2007. The National Provider Identifier (NPI) number assigned to this provider is 1104034230.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rahul Shimpi, MD has received a total of $7,338 in payments from pharmaceutical and medical device companies, with $7,068 received in 2024. These payments were reported across 31 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($5,600).
As a Medicare-enrolled provider, Shimpi has provided services to 2,287 Medicare beneficiaries, totaling 3,310 services with total Medicare billing of $241,765. Data is available for 4 years (2020–2023), covering 64 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Clayton, NC
- Active Since 05/21/2007
- Last Updated 05/22/2025
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1104034230
Products in Payments
- UPLIZNA (Biological) $6,586
- XIFAXAN (Drug) $191.92
- OCALIVA (Drug) $119.91
- RINVOQ (Biological) $115.99
- IBSRELA (Drug) $48.77
- REBYOTA (Biological) $42.30
- BRAVO (Device) $40.41
- Axonics (Device) $23.17
- RESMETIROM (Drug) $22.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.